Payment overview · 2025
General Payments
$383.46
13 reported records · 6 companies
Healthcare provider profile · identity verified
Maria B Bello, MD
Allopathic & Osteopathic Physicians|Family Medicine · LEESBURG, FL · NPI 1821081563
Verified facts
What the public records show
CMS Open Payments records show Maria B Bello, MD received $383.46 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $175.49 | 45.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.80 | 16.1% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $51.86 | 13.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.88 | 10.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.10 | 7.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.33 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.46 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $124.01 | 1 | 2025 |
Source payment records
|
|||||
| MUSTANG Normalized: mustang |
Device | Boston Scientific Corporation | $51.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
187 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1201 | 355 |
| Levothyroxine Sodium | Levothyroxine Sodium | 894 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 772 | 241 |
| Lisinopril | Lisinopril | 692 | 208 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 558 | 166 |
| Omeprazole | Omeprazole | 497 | 161 |
| Simvastatin | Simvastatin | 452 | 134 |
| Losartan Potassium | Losartan Potassium | 438 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 119 |
| Montelukast Sodium | Montelukast Sodium | 345 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 275 | 86 |
| Gabapentin | Gabapentin | 273 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 85 |
| Metformin Hcl | Metformin Hcl | 246 | 81 |
| Trazodone Hcl | Trazodone Hcl | 220 | 82 |
| Carvedilol | Carvedilol | 217 | 64 |
| Sertraline Hcl | Sertraline Hcl | 201 | 54 |
| Atenolol | Atenolol | 190 | 55 |
| Ozempic | Semaglutide | 187 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 54 |
| Furosemide | Furosemide | 166 | 54 |
| Meloxicam | Meloxicam | 166 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 51 |
| Allopurinol | Allopurinol | 152 | 42 |
| Alendronate Sodium | Alendronate Sodium | 132 | 39 |
| Tramadol Hcl | Tramadol Hcl | 132 | 33 |
| Famotidine | Famotidine | 126 | 40 |
| Potassium Chloride | Potassium Chloride | 126 | 37 |
| Synthroid | Levothyroxine Sodium | 118 | 31 |
| Prednisone | Prednisone | 109 | 95 |
| Buspirone Hcl | Buspirone Hcl | 104 | 37 |
| Glipizide | Glipizide | 96 | 29 |
| Metformin Hcl Er | Metformin Hcl | 96 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 37 |
| Lorazepam | Lorazepam | 90 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 33 |
| Ezetimibe | Ezetimibe | 84 | 30 |
| Donepezil Hcl | Donepezil Hcl | 82 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 80 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 28 |
| Telmisartan | Telmisartan | 76 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 34 |
| Bupropion Hcl Sr | Bupropion Hcl | 72 | 20 |
| Lovastatin | Lovastatin | 72 | 21 |
| Jardiance | Empagliflozin | 70 | 19 |
| Mirtazapine | Mirtazapine | 69 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 15 |
| Bupropion Xl | Bupropion Hcl | 62 | 21 |
| Celecoxib | Celecoxib | 61 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 18 |
| Eliquis | Apixaban | 58 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Pregabalin | Pregabalin | 56 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 24 |
| Glimepiride | Glimepiride | 55 | 16 |
| Clonazepam | Clonazepam | 54 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Valacyclovir | Valacyclovir Hcl | 53 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 36 |
| Estradiol | Estradiol | 50 | 18 |
| Mounjaro | Tirzepatide | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 23 |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 42 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 12 |
| Finasteride | Finasteride | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 14 |
| Enalapril Maleate | Enalapril Maleate | 37 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Fluconazole | Fluconazole | 34 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 22 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Acyclovir | Acyclovir | 32 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Ciclopirox | Ciclopirox | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 13 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Ramipril | Ramipril | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.46 · 13 records | PFIZER INC. | Cologuard Collection Kit, GEMTESA, KISUNLA, MOUNJARO, MUSTANG, NURTEC ODT, Ozempic, Rybelsus, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error